Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination medication containing **caffeine**, **carisoprodol**, **diclofenac**, and **paracetamol (acetaminophen)**. This formulation is intended for the treatment of **pain and inflammation** of various etiologies. - **Caffeine** acts as a central nervous system stimulant and is sometimes included to enhance the analgesic effects of other agents. - **Carisoprodol** is a centrally acting muscle relaxant used to relieve muscle spasms associated with acute musculoskeletal conditions. - **Diclofenac** is a nonsteroidal anti-inflammatory drug (NSAID), primarily acting as a cyclooxygenase (COX) inhibitor, thereby reducing inflammation and pain. - **Paracetamol (Acetaminophen)** is an analgesic and antipyretic, believed to act mainly in the central nervous system by inhibiting prostaglandin synthesis. The combination is not widely approved or standard in many regions; fixed-dose combinations of multiple analgesics and muscle relaxants are more typical in certain countries for short-term management of acute pain, though concerns exist about additive toxicity and potential for adverse effects[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + carisoprodol + diclofenac + paracetamol.